Loading...
Market
Story
Roche Halts SKYSCRAPER-06 Lung Cancer Drug Trial After Failing to Show Benefit
Jul 4, 2024, 08:03 AM
Roche has announced the termination of its Phase II/III SKYSCRAPER-06 clinical trial for metastatic non-squamous non-small cell lung cancer. The trial, which combined the PD-L1 inhibitor atezolizumab with the TIGIT inhibitor tiragolumab and chemotherapy, failed to demonstrate a significant benefit in overall survival (OS) and progression-free survival (PFS) compared to the control group. The hazard ratios for OS and PFS were 1.33 and 1.27, respectively, with 95% confidence intervals. This decision marks a significant setback for Roche's lung cancer immunotherapy efforts, particularly in comparison to established treatments like Merck's Keytruda. The trial was conducted under the ticker $RHHBY.
View original story
Similar markets
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%
Breast cancer • 25%
Lung cancer • 25%
Colorectal cancer • 25%
Other cancer types • 25%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%